Results 91 to 100 of about 2,457 (125)

Modeling Cystic Fibrosis Patient-Specific Responses to CFTR Modulators Using Human Induced Pluripotent Stem Cells. [PDF]

Am J Respir Crit Care Med
Kanagarajah KR, Wu MJM, Lam T, Quach HT, Salih R, Antonio K, Moraes TJ, Ratjen F, Bear CE, Wong AP.   +9 more
europepmc   +1 more source

Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis: A Review of Registry-Based Evidence. [PDF]

J Clin Med
Salvatore D, Pepe A.
europepmc   +1 more source

Unraveling PPARβ/δ nuclear receptor agonists <i>via</i> a drug-repurposing approach: HTVS-based ligand identification, molecular dynamics, pharmacokinetics, and <i>in vitro</i> anti-steatotic validation. [PDF]

RSC Adv
Mandal SK, Muzaffar-Ur-Rehman M, Puri S, Kumar BK, Sharma PK, Sankaranarayanan M, Deepa PR.   +6 more
europepmc   +1 more source

Beyond BMI: Nutritional Recovery and Functional Implications of CFTR Modulators in Cystic Fibrosis. [PDF]

Biology (Basel)
Linguiti G, Granberg V, Leonetti G, Lassandro G, Lassandro M, Delvecchio M, Giordano P.   +6 more
europepmc   +1 more source

Lumacaftor/ivacaftor for cystic fibrosis

, 2019
openaire   +1 more source

Lumacaftor/ivacaftor for cystic fibrosis.

Australian prescriber
openaire   +1 more source